|Articles|September 9, 2022
- Pharmaceutical Executive-09-01-2022
- Volume 42
- Issue 9
Pharmaceutical Executive, September 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 3 years ago
ESG: Applying Lessons From Consumer Marketabout 3 years ago
21st Annual Industry Audit: Pharma Performance Checkabout 3 years ago
The Manufacturing Edge on Path to Marketabout 3 years ago
How Good is a Good Product Launch?about 3 years ago
More Than a Name: Vyvgartabout 3 years ago
Fighting Vision Loss: Vabysmoabout 3 years ago
A Sleeping Giant?: Quviviqabout 3 years ago
Next-level Efficacy: MounjaroNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5
